pharma · CXCR4 · Uterine Cervical Neoplasms
Zhongnan Hospital
Zhongnan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include CXCR4, Uterine Cervical Neoplasms. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent recor
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 2
- Drugs
- 5
- Patents
- 0
Hydrochloride anlotinib
Unknown · small molecule · Uterine Cervical Neoplasms
Hydrochloride anlotinib for Uterine Cervical Neoplasms is a Unknown program (small_molecule) at Zhongnan Hospital with 1 ClinicalTrials.gov record(s).
Internal code CC-RT-ALTER-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Zhongnan Hospital
- Phase
- Unknown
- Modality
- small_molecule
- Indication
- Uterine Cervical Neoplasms
- Status
- active
- Trials
- 1